• February 25, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved SimparicaTM (sarolaner) Chewables to kill adult fleas and prevent flea infestations, as well as treat and control tick infestations due to the Lone Star tick, the Gulf Coast tick, the American dog tick, and the brown dog tick. Simparica is approved for use in dogs 6 months of age or older and weighing 2.8 pounds or more. In a single-dose, tastymore...
  • February 23, 2016
    PUERTO MONTT, CHILE - PHARMAQ's vaccine ALPHA JECT LiVac® SRS received a provisional marketing authorisation (PMA number 2320-BP) from the Chilean authority, Servicio Agrícola y Ganadero de Chile (SAG). "Our innovative drive is based on the aquaculture industry's need to produce safe and healthy seafood. We are confident that this ground-breaking vaccine will be an important tool to help fight SRS. This is a highly requested product by the industry and will help achieve more predictable andmore...
  • February 19, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a second quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share. The dividend is to be paid on Wednesday, June 1, 2016, to holders of record on Thursday, April 7, 2016. About Zoetis Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on moremore...
  • February 17, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Barclays Global Healthcare Conference on Wednesday, March 16, 2016, in Miami, Fla. Clint Lewis, Executive Vice President and President, International Operations, will represent the company and respond to questions from analysts. He is scheduled to present at 9:00 a.m. EDT. Investors and other interested parties will be able to access a live audio webcast of the presentation bymore...
  • February 16, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2015 and updated its guidance for full year 2016 and 2017. The company reported revenue of $1.3 billion for the fourth quarter of 2015, a decrease of 3% from the fourth quarter of 2014. Revenue reflected an operational1 increase of 6%, excluding the impact of foreign currency. Net income for the fourth quarter of 2015more...
  • January 12, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) provided the following statement concerning the European Commission’s decision regarding existing tax rulings in Belgium, and gave its implications for the company’s financial guidance for 2016 and 2017: Zoetis is disappointed with the European Commission’s announcement regarding Belgium’s tax rulings and its implications for Zoetis. The company complies with all tax laws and has relied on these long-standingmore...
  • December 30, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, Feb. 16, 2016. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Paul Herendeen will review fourth quarter and full year financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetismore...
  • December 16, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a first quarter 2016 dividend payable to holders of the company’s common stock of $0.095 per share, an increase of 14.5% from the quarterly dividend rate paid in 2015. The dividend is to be paid on Tuesday, March 1, 2016, to holders of record on Thursday, Jan. 21, 2016. “Zoetis has continued to distinguish itself as a world leader in the growing animal health industrymore...
  • December 14, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2016, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. EST (9:30 a.m. PST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visitingmore...
  • November 17, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted marketing authorization for SimparicaTM (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age. The approval follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use in September 2015. “The approval of Simparica givesmore...